Cellectis S.A.

DB:ZVA Stock Report

Market Cap: €165.6m

Cellectis Valuation

Is ZVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ZVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ZVA (€1.66) is trading above our estimate of fair value (€1.64)

Significantly Below Fair Value: ZVA is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZVA?

Key metric: As ZVA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ZVA. This is calculated by dividing ZVA's market cap by their current revenue.
What is ZVA's PS Ratio?
PS Ratio4.7x
SalesUS$36.04m
Market CapUS$170.61m

Price to Sales Ratio vs Peers

How does ZVA's PS Ratio compare to its peers?

The above table shows the PS ratio for ZVA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10x
HPHA Heidelberg Pharma
13.5x16.6%€114.6m
MDG1 Medigene
2x16.4%€15.1m
FYB Formycon
15.8x24.6%€958.8m
2INV 2invest
8.7xn/a€67.3m
ZVA Cellectis
4.7x23.9%€165.6m

Price-To-Sales vs Peers: ZVA is good value based on its Price-To-Sales Ratio (4.7x) compared to the peer average (10x).

Price to Sales Ratio vs Industry

How does ZVA's PS Ratio compare vs other companies in the DE Biotechs Industry?

5 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
ZVA 4.7xIndustry Avg. 8.3xNo. of Companies5PS0612182430+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ZVA is good value based on its Price-To-Sales Ratio (4.7x) compared to the European Biotechs industry average (8.3x).

Price to Sales Ratio vs Fair Ratio

What is ZVA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZVA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.7x
Fair PS Ratio3.6x

Price-To-Sales vs Fair Ratio: ZVA is expensive based on its Price-To-Sales Ratio (4.7x) compared to the estimated Fair Price-To-Sales Ratio (3.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 14:49
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cellectis S.A. is covered by 21 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Madhu KumarBaird
Huidong WangBarclays